Our previous results suggest that SHP-1-dependent STAT3 inhibition is a target of sorafenib and that the activated function of SHP-1 phosphatase that targets STAT3 may be a promising candidate for targeted cancer therapy and drug discovery [12,23,24]. Here, STAT3 is linked to cancer.